靶向超声在预测对比增强数字乳腺摄影检出病灶恶性中的效用
回顾性分析153个CEM检出的不确定或可疑强化病灶,47个(31%)有US对应,肿块强化者对应率高于非肿块强化,有US对应者恶性率高于无对应者,US引导活检PPV为32%。结论认为有US对应的CEM强化病灶更可能为恶性,可行US引导活检以避免额外乳腺MRI。
要点
- CEM检出强化病灶中仅31%(47/153)有靶向US对应,肿块强化对应率65%高于非肿块强化17%。
- 有US对应病灶恶性率26%(12/47),无US对应10%(11/106),差异有统计学意义。
- US引导活检PPV为32%,有US对应者可替代额外乳腺MRI进行活检。
关键影像表现/征象
- CEM强化肿块中65%(28/43)有US对应,非肿块强化中17%(19/110)有US对应(p < .001)。
- 有US对应的强化病灶恶性率26%(12/47),无US对应者10%(11/106)(p = .03)。
- 肿块病灶恶性率26%(11/43),非肿块病灶11%(12/110)(p = .04)。
诊断标准与关键数值
- US引导活检的阳性预测值(PPV)为32%。
- 以组织病理学为活检病灶参考标准,未活检病灶以随访影像为参考标准。
- CEM强化类型分为肿块强化与非肿块强化,US对应定义为靶向US可发现对应病灶。
临床应用与阅片要点
- CEM检出不确定或可疑强化病灶时,靶向US发现对应病灶提示恶性可能性更高,可将其作为US引导活检的靶点。
- 有US对应的CEM强化病灶可经US引导活检,从而避免额外乳腺MRI。
- 作者指出在CEM活检系统商业化之前,CEM导向的US对强化病灶有应用价值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Targeted ultrasound (US) can be performed to characterize and potentially biopsy areas of enhancement detected on contrast-enhanced mammography (CEM). OBJECTIVE. The purpose of this study was to assess the utility of targeted US in predicting malignancy of lesions with indeterminate or suspicious enhancement on CEM. METHODS. One thousand consecutive CEM examinations with same-day targeted breast US at one institution between October 2013 and May 2018 were retrospectively reviewed. All patients with indeterminate or suspicious enhancement detected on CEM that underwent US evaluation were included. Patients with palpable or symptomatic lesions, those with suspicious findings on low-energy mammograms or images obtained with another modality, and those with less than 1 year of follow-up were excluded. Medical records, imaging, and pathology data were reviewed. Histopathologic analysis was used as the reference standard for biopsied lesions, and follow-up imaging was used for unbiopsied lesions. Associations between pathologic diagnosis, presence of a US correlate, and lesion characteristics were assessed by Fisher exact, chi-square, and Wilcox-on rank sum tests. RESULTS. Among 153 enhancing lesions detected on CEM in 144 patients, 47 (31%) had a US correlate. The frequency of a correlate between CEM and US was significantly higher among enhancing masses (28/43 [65%]) than among lesions exhibiting nonmass enhancement (19/110 [17%]) (p < .001). The likelihood of malignancy was significantly greater among lesions with a US correlate (12/47 [26%]) than among those without a US correlate (11/106 [10%]) (p = .03), and among mass lesions (11/43 [26%]) than among nonmass lesions (12/110 [11%]) (p = .04). The PPV of US-guided biopsy after CEM-directed US was 32%. CONCLUSION. Enhancing CEM-detected lesions that have a US correlate are more likely to be malignant and can be evaluated with US-guided biopsy to obviate additional breast MRI. CLINICAL IMPACT. CEM-directed US of enhancing lesions is useful given that lesions with a US correlate are more likely to be malignant and can be used as targets for US-guided biopsy until a CEM biopsy system becomes commercially available.
引用
- Coffey K, Sung J, Comstock C, et al. Utility of Targeted Ultrasound to Predict Malignancy Among Lesions Detected on Contrast-Enhanced Digital Mammography. AJR Am J Roentgenol. 2020. PMID: 33025811. doi:10.2214/AJR.20.24368
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。